Leigh Anne Siino’s Post

Early post-operative lactate increase following kidney transplant is associated with delayed graft function Two hundred 12 patients were included, and 38 (17.9%) developed DGF. Venous lactate variation between H0 and H4 was higher in patients who developed DGF (-30 (IQR -83, -6)% vs. -15 (IQR -62, -11)%, p = .037), but the variation of level was more often positive (corresponding to an increased lactate production over time between H0 and H4) in patients who developed DGF ((28(85%) vs. 94(62%), p = .011). In multivariate logistic regression, positive venous lactate level variation between H0 and H4 was strongly associated with a reduced risk of developing DGF (OR .30 [.09-.79], p = .024).   Early venous lactate variation after kidney transplant could help to predict the occurrence of DGF. (Deniau B, Sen J, Chaussard M, Boutin L, Coutrot M, Guillemet L, Plaud B, Depret F, Dudoignon E. Early post-operative lactate increase following kidney transplant is associated with delayed graft function: A retrospective cohort study. Clin Transplant. 2024 Mar;38(3):e15288. doi: 10.1111/ctr.15288. PMID: 38520246.) Eaglenos #LacateMeter #BloodGasAnalyzer

Angiopoietin-2, vascular endothelial growth factor family, and heparin binding endothelial growth factor are associated with subclinical atherosclerosis in rheumatoid arthritis. Read the article here: https://lnkd.in/gatnjKC8

Article Title: Primary Biliary Cholangitis and Rheumatoid Arthritis: An Emerging Association   Journal of Case Reports and Medical History (JCRMH) Acquire Publications Authors: Safaa Mourabit Abstract Primary Biliary Cholangitis (PBC), formerly known as primary biliary cirrhosis, is an autoimmune-related cholestatic hepatopathy, representing a common cause of intrahepatic cholestasis due to progressive bile duct destruction. Often, PBC is linked with other autoimmune disorders such as Sjogren’s syndrome, thyroid dysfunction, scleroderma, and systemic lupus erythematosus. However, the association of PBC with rheumatoid arthritis (RA) is rare, estimated at 1.8 to 5.6%. We present a clinical case of PBC discovered in a patient with deforming rheumatoid arthritis. For full Article visit https://lnkd.in/gaFmG2Ap

Our latest paper summary by Cho, et al., “Comparative Effectiveness of Tofacitinib and Tumour Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis in Real-world Practice: A Prospective Observational Study”, compared the rates of remission in South Korean patients with RA over a 12-month period. The authors found no significant differences in the rates or remission between tofacitinib and TNFi. Find out more on the IMID Forum, completely free and stay up to date with the latest research findings in #RhematoidArthritis https://ow.ly/pq7u50R44RC

Study findings support initial use of voclosporin-based triple immunosuppression including low-dose glucocorticoids for proteinuria reduction in patients with #lupus nephritis. https://brnw.ch/21wLE8Y

Check out our latest article summarizing post-hoc analyses of the phase III TULIP-LTE trial in patients with systemic lupus erythematosus treated with anifrolumab, presented at #ACR23. 👉 https://loom.ly/ZZ2pi-s #MedEd #lupus

"It is a very good concept", "I am delighted to be engaged" and "This is consistant with the scientific work we have been doing" - 3 quotes from three leading USA rheumatologists. Thank you for advising us, Prof. Dr. #Joel_Kremer, #Stanley_Cohen and #Michael_Weinberg, three real-world experts when it comes to the use, efficacy and safety of the #cornerstone_treatment of #rheumatoid_arthritis, low-dose #methotrexate. The founding fathers of the #CORRONA database (nowadays the CorEvitas, LLC Rheumatoid Arthritis database) and pioneers when it comes to understanding the mode of action of methotrexate: clinical efficacy is directly correlated to intracellular polyglutamation of methotrexate. The latter, of course, can only happen if methotrexate and its polyglutamated intermediates are retained in the target cells! At Amplio Pharma we are committed to developing #MethotrexateForte. Our objective: a better and faster clinical response in more patients, an improved efficacy/safety profile, and an overall treatment-cost reduction in the immune-mediated inflammatory disease area. Our solution is simple and elegant: #trap_methotrexate in the target cell by closing its exit door (the ABCG2 efflux protein) with the #repurposed natural compound #novobiocin.

I came across this insightful article discussing the early use of mycophenolate mofetil (MMF) in treating newly diagnosed systemic lupus erythematosus (SLE). The study highlights how MMF, alongside prednisone and hydroxychloroquine, can significantly reduce severe flares and the risk of lupus nephritis in newly diagnosed SLE patients without major organ involvement. It takes just 1 minute to read! Check out the full article for more details: https://lnkd.in/d4mSerkA

Rheumatoid Arthritis Awareness Day is observed on February 2 each year. The Rheumatoid Patient Foundation started this day to spread awareness about the condition. Rheumatoid Arthritis is one of the most common autoimmune conditions that attacks joints and causes inflammation. There is no cure, but it can go into remission with proper and timely care.   On the occasion of RA Awareness Day, we would like to highlight the importance of new biological therapies in Rheumatoid Arthritis. At our new clinical trial site, in Qualiclinic, 3 new studies are being launched in this indication.   #clinicaltrilas #clinicalresearch #rheumatoidarthritis #rheumaticdisorder #RA #RAAD2024

More than 23 million people live with arthritis worldwide, with rheumatoid arthritis being one of the most severe forms. Recent advancements in clinical trials have led to the emergence of new biologic therapies that offer significant improvements in pain management and joint function. Biopharma Informatic invites you to participate in our rheumatoid arthritis trials, where you can receive advanced care while contributing to the development of life-changing therapies. #ArthritisAwareness #FightArthritis #ArthritisSupport #StrongerThanArthritis #RheumatoidArthritis #clinicaltrials #BiopharmaInformatic